Unknown

Dataset Information

Targeted therapies in urothelial carcinoma.


ABSTRACT:

Purpose of review

Greater understanding of the biology and genetics of urothelial carcinoma is helping to identify and define the role of molecules and pathways appropriate for novel-targeted therapies. Here, we review the targeted therapies that have been reported or are in ongoing urothelial carcinoma clinical trials, and highlight molecular targets characterized in preclinical and clinical studies.

Recent findings

Trials in nonmuscle-invasive bladder cancer are evaluating the role of immunotherapy and agents targeting vascular endothelial growth factor (VEGF) or fibroblast growth factor receptor-3. In muscle-invasive bladder cancer, neoadjuvant studies have focused on combining VEGF agents with chemotherapy; adjuvant studies are testing vaccines and agents targeting the h

SUBMITTER: Ghosh M 

PROVIDER: S-EPMC6777561 | biostudies-literature | 2014 May

REPOSITORIES: biostudies-literature